ストックスクリーナーアプリを入手
19.80
3.13%
0.60
前日終値:
$19.20
開ける：
$20
24時間の取引高:
5.11M
Relative Volume:
2.85
時価総額：
$3.27B
収益：
-
当期純損益:
$-451.71M
株価収益率:
-6.1374
EPS:
-3.2261
ネットキャッシュフロー:
$-462.19M
1週間 パフォーマンス:
+10.31%
1か月 パフォーマンス:
+19.71%
6か月 パフォーマンス:
+6.74%
1年 パフォーマンス:
+83.67%
1日の値動き範囲:
$19.14
$20.48
1週間の範囲:
$17.64
$20.48
52週間の値動き範囲:
$8.06
$25.00
Dyne Therapeutics Inc Stock (DYN) Company Profile
Compare DYN vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
19.80 | 3.27B | 0 | -451.71M | -462.19M | -3.2261 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-10 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-10-10 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-08-25 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2025-06-24 | 開始されました | Bernstein | Mkt Perform |
| 2025-06-11 | 再開されました | Raymond James | Outperform |
| 2025-06-02 | 再開されました | Oppenheimer | Outperform |
| 2025-05-29 | 開始されました | Evercore ISI | Outperform |
| 2025-03-12 | 開始されました | BMO Capital Markets | Outperform |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-12-13 | 開始されました | Robert W. Baird | Outperform |
| 2024-11-26 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-10-24 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-05-21 | 繰り返されました | Chardan Capital Markets | Buy |
| 2024-04-30 | 開始されました | Morgan Stanley | Overweight |
| 2024-02-20 | 開始されました | H.C. Wainwright | Buy |
| 2023-02-27 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | 開始されました | Oppenheimer | Outperform |
| 2023-01-26 | 開始されました | Guggenheim | Buy |
| 2022-07-20 | 開始されました | Chardan Capital Markets | Buy |
| 2022-07-12 | 開始されました | Raymond James | Outperform |
| 2020-10-12 | 開始されました | JP Morgan | Overweight |
| 2020-10-12 | 開始されました | Jefferies | Buy |
| 2020-10-12 | 開始されました | Piper Sandler | Overweight |
| 2020-10-12 | 開始されました | Stifel | Buy |
すべてを表示
Dyne Therapeutics Inc (DYN) 最新ニュース
Dyne Therapeutics (DYN) RBC Capital Markets Global Healthcare Conference 2026 summary - Quartr
Dyne Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(4) - marketscreener.com
Dyne Therapeutics Inc (DYN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Dyne Therapeutics Inc (DYN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Dyne Therapeutics Inc (DYN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Dyne awards stock options, RSUs to 6 newly hired employees - Stock Titan
Dyne Therapeutics Inc (DYN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Dyne Therapeutics Inc (DYN) Institutional Confidence - TradingKey
Dyne Therapeutics Inc (DYN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc. - Investing News Network
Dyne therapeutics CEO John Cox sells $49,179 in stock - Investing.com UK
Dyne Therapeutics (DYN) CMO auto-sells shares to cover tax withholding - Stock Titan
Dyne Therapeutics (DYN) CCO auto-sells shares to cover RSU tax withholding - Stock Titan
Dyne Therapeutics (NASDAQ: DYN) CEO logs automatic RSU tax sale - Stock Titan
ForDyne B.V. (DYN) reports multiple April 2026 resale lots totaling millions - Stock Titan
Dyne Therapeutics Inc (DYN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Dyne Therapeutics Expands Hercules Capital Debt Facility to Up to $400 Million - citybiz
Dyne Therapeutics Shares Rise After Amendment to Debt Facility - marketscreener.com
Dyne Therapeutics, Inc. 8-K SEC Filing: Company Details, Stock Info, and Regulatory Compliance (June 2026) - Minichart
Dyne Therapeutics Expands Loan Facility to $400 Million with Hercules Capital Amendment - marketscreener.com
Dyne Therapeutics amends loan agreement to expand debt facility to $400 million - Investing.com UK
Dyne Therapeutics amends loan facility, secures $50 million - Investing.com
Dyne Therapeutics amends loan facility, secures $50 million By Investing.com - Investing.com India
Dyne Therapeutics Expands Hercules Loan Facility to $400 Million, Draws $50 Million Tranche - TradingView
Dyne Therapeutics (NASDAQ: DYN) boosts Hercules loan capacity to $400M - Stock Titan
Dyne Secures $400M War Chest to Push Rare Disease Drugs to Market - BriefGlance
Dyne Therapeutics Secures $125 Million in Additional Financing - Intellectia AI
DYN (Nasdaq: DYN) affiliate sale of 3,311 shares; 9,081 RSUs listed - Stock Titan
DYNE THERAPEUTICS INC (DYN) Stock Chart - ChartMill
Dyne Therapeutics Inc (DYN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Trading Systems Reacting to (DYN) Volatility - Stock Traders Daily
Dyne Therapeutics (DYN) Concludes Phase 1/2 ACHIEVE Trial Enrollment - Insider Monkey
Clearbridge Investments LLC Makes New Investment in Dyne Therapeutics, Inc. $DYN - MarketBeat
Cibc World Market Inc. Takes Position in Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne therapeutics director Brian Posner buys $33,880 in stock By Investing.com - Investing.com Nigeria
Dyne therapeutics director Brian Posner buys $33,880 in stock - Investing.com
Insider Buying: Brian Posner Acquires Additional Shares of Dyne Therapeutics Inc (DYN) - GuruFocus
Director at Dyne Therapeutics (DYN) receives 35,152 stock options - Stock Titan
Director Lubner gets 35,152 Dyne (DYN) options at $17.04 strike - Stock Titan
Dyne Therapeutics director granted 35,152 options | DYN Insider Trading - Stock Titan
Director at Dyne Therapeutics (NASDAQ: DYN) granted 35,152 stock options at $17.04 - Stock Titan
Director at Dyne Therapeutics (DYN) receives grant of 35,152 stock options - Stock Titan
Dyne Therapeutics (DYN) director buys stock and receives 35,152-share option grant - Stock Titan
Dyne Therapeutics (DYN) investors double share authorization and approve all proposals - Stock Titan
Dyne spikes as late-stage trial for Duchenne therapy gets underway - MSN
Dyne Therapeutics (DYN) director Brian Posner buys 2,500 shares in open market - Stock Titan
Dyne Therapeutics (DYN) Reaches Key Regulatory Milestone - Insider Monkey
A Look At Dyne Therapeutics (DYN) Valuation After Key ACHIEVE Trial Enrollment Milestone - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Evercore Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $33 - Moomoo
Dyne Therapeutics Inc (DYN) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):